ALSYMPCA Articles

Since November 2013, the alpha emitter radium-223 dichloride (Alpharadin/Xofigo®) has been approved for the treatment of men with castration-resistant prostate cancer (CRPC) with symptomatic bone metastases and no known visceral metastatic disease.

Baseline clinical variables are prognostic for overall survival (OS) in patients with castration-resistant prostate cancer (CRPC). Their prognostic and predictive value with agents targeting bone metastases, such as radium-223, is not established.

BERKELEY, CA (UroToday.com) - The treatment of metastatic castrate resistant prostate cancer (mCRPC) has changed drastically over the past few years with the emergence of several new therapies.

CHICAGO, IL USA (UroToday.com) - Presented by Nicholas Vogelzang, MDat the American Society of Clinical Oncology (ASCO) Annual Meeting - May 31 - June 4, 2013 - McCormick Place - Chicago, IL USA

CHICAGO, IL USA (UroToday.com) - Presented by N.J. Vogelzang,¹ S.I. Helle,,² D.C. Johannessen,³ J.M. O’Sullivan,⁴ J. Garcia-Vargas,⁵ C.G. O’Bryan-Tear,⁶ M. Shan,⁵ and C. Parker⁷at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 31 - June 4, 2013 - McCormick Place - Chicago, IL USA

CHICAGO, IL USA (UroToday.com) - Presented by C. Parker,¹ J. Garcia-Vargas,² C.G. O’Bryan-Tear,³ F. Fang,² N.J. Vogelzang⁴ at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 31 - June 4, 2013 - McCormick Place - Chicago, IL USA

CHICAGO, IL USA (UroToday.com) - Presented by S. Nilsson,¹ O. Sartor,² Ø. Bruland,³ F. Fang,⁴A-K. Aksnes,⁵ P. Cislo,⁴ C. Parker⁶ at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 31 - June 4, 2013 - McCormick Place - Chicago, IL USA

SAN DIEGO, CA USA (UroToday.com) - Metastases to the bone are found in > 90% of men with castration resistant prostate cancer. Thus, Radium 223, a first-in-class, alpha-emitting pharmaceutical agent, has garnered excitement as a new treatment option imparting a survival advantage in this patient population.

Listen to Dr. Sartor from Tulane University present new data from the phase III ALSYMPCA trial (ALpharadin in SYMptomatic Prostate CAncer) in this podcast: "Radium-223 Chloride (Alpharadin) in Patients With Bone Metastases and Castration-Resistant Prostate Cancer (CRPC): A New Treatment Paradigm"

In Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial, radium-223 versus placebo prolonged overall survival with favorable safety in castration-resistant prostate cancer patients with symptomatic bone metastases.